抗 CD7 异体 WU-CART-007 治疗复发/难治性 T 细胞急性淋巴细胞白血病/淋巴瘤：一项 1/2 期试验

Relapsed/refractory T-cell acute lymphoblastic leukemia (ALL)/lymphoma (LBL) represent a significant unmet medical need. WU-CART-007 is a CD7-targeting, allogeneic, fratricide-resistant chimeric antigen receptor T cell product generated from healthy donor T cells. WU-CART-007 was evaluated in a phase 1/2 study with a 3 + 3 dose-escalation design followed by cohort expansion in relapsed/refractory T-ALL/LBL. Patients received one infusion of WU-CART-007 after standard or enhanced lymphodepleting chemotherapy. The primary objectives, to characterize safety and assess the composite complete remission rate, were met. Of 26 patients enrolled, 13 received the recommended phase 2 dose (RP2D) of 900 million cells of WU-CART-007 with enhanced lymphodepletion.

The most common treatment-related adverse event was cytokine release syndrome (88. 5%; 19. 2% grade 3-4). Biochemical abnormalities consistent with grade 2 hemophagocytic lymphohistiocytosis were seen in one patient (3. 8%). Grade 1 immune effector cell-associated neurotoxicity syndrome events (7. 7%) and one grade 2 acute graft-vs-host disease event occurred. Grade 5 events (11.

5%) were due to fungal infection and multi-organ failure. The composite complete remission rate was 81. 8% among 11/13 patients evaluable for response at the RP2D. WU-CART-007 at the RP2D demonstrated a high response rate in patients with relapsed/refractory T-ALL/LBL and has the potential to provide a new treatment option. ClinicalTrials. gov registration: NCT04984356.